A Confirmatory Phase III Study of BEKINDA 24 mg for Acute Gastroenteritis or Gastritis
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Ondansetron (Primary)
- Indications Gastritis; Gastroenteritis
- Focus Registrational; Therapeutic Use
- Sponsors RedHill Biopharma
- 09 Apr 2018 According to a RedHill Biopharma media release, the company is currently in discussions with the FDA on the design of this confirmatory phase III study to support a potential New Drug Application (NDA).
- 11 Oct 2017 New trial record
- 03 Oct 2017 According to a RedHill Biopharma media release, data from this trial will support a New Drug Application (NDA) with BEKINDA 24 mg for acute gastroenteritis and gastritis.